# **PCFBANK**

1221

10100

### Interim Results FY22

June 2022

### Disclaimer

THIS PRESENTATION MAY NOT BE COPIED OR REPRODUCED IN ANY FORM, FURTHER DISTRIBUTED OR PASSED ON, DIRECTLY OR INDIRECTLY, TO ANY OTHER PERSON, OR PUBLISHED, IN WHOLE OR IN PART, FOR ANY PURPOSE. IN PARTICULAR, THIS PRESENTATION AND ITS CONTENTS ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN OR ANY JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL. ANY FAILURE TO COMPLY WITH THESE RESTRICTIONS MAY CONSTITUTE A VIOLATION OF APPLICABLE SECURITIES LAWS.

This presentation does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of the Company, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract commitment or investment decision in relation thereto.

The information contained in this presentation has been prepared by PCF Group plc ("PCF" or the "Company"). It has not been fully verified and is subject to material updating, revision and further amendment. This presentation has not been approved by an authorised person in accordance with Section 21 of the Financial Services and Markets Act 2000 ("FSMA") and therefore it is being delivered for information purposes only to a very limited number of persons and companies who are persons who have professional experience in matters relating to investments and who fall within the category of person set out in Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or are high net worth companies within the meaning set out in Article 49 of the Order or are otherwise permitted to receive it. Any other person who receives this presentation should not rely or act upon it. By accepting this presentation and not immediately returning it, the recipient represents and warrants that they are a person who falls within the above description of persons entitled to receive the presentation. This presentation is not to be disclosed to any other person or used for any other purpose.

While the information contained herein has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this presentation, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as "Information") and liability therefore is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this presentation. In particular, unless expressly stated otherwise, the financial information contained in this presentation relates to the Company and its subsidiary undertakings.

Neither the issue of this presentation nor any part of its contents is to be taken as any form of commitment on the part of the Company to proceed with any transaction and the right is reserved to terminate any discussions or negotiations with any prospective investors. In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. In furnishing this presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this presentation or to correct any inaccuracies in, or omissions from, this presentation which may become apparent.

This presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. In particular, this presentation does not constitute an offer or invitation to subscribe for or purchase any securities and neither this presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever. Each party to whom this presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.

This presentation and the information contained herein are not an offer of securities for sale and are not for publication and or distribution in the United States or to any US person (within the meaning of Regulation S under the United States Securities Act of 1933, as amended (the "Securities Act")) or in Canada, Australia, South Africa or Japan or any jurisdiction where such offer or distribution is unlawful. Any failure to comply with this restriction may constitute a violation of United States securities laws.

The securities of the Company have not been registered under the Securities Act and may not be offered or sold in the United States or to any US person unless the securities are registered under the Securities Act or an exemption therefrom is available.

Certain statements in this presentation may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "potential," "estimate," "predict," "potential," or "continue" or the negative of these terms or other comparable terminology. You should not place reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could materially affect actual results, the acquisition, levels of activity, performance, or achievements. Any forward-looking statements are based on currently available competitive, financial and economic data together with management's views and assumptions regarding future events and business performance as of the time the statements are made and are subject to risks and uncertainties. We wish to caution you that there are some known and unknown factors that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Reference should be made to those documents that PCF shall file from time to time or announcements that may be made by PCF in accordance with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and any projections or forward-looking statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, PCF does not undertake any obligation to publicly update or revise any forward-looking statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, PCF does not undertake any obligation to publicly update or revise any forward-looking statements above. Except as may

### **Performance Overview**

Operational Performance	LENDING NEW BUSINESS ORIGINATIONS <sup>1</sup> <b>40%</b> <b>662m</b> (H1 2021: £104m) Portfolio in top four credit grades		LENDING GROSS LOANS AND ADVANCES <b>V 12%</b> 6332m (Sep 2021: £376m) Segmental split		FUNDING RETAIL DEPOSITS 7,600 customers £291m (Sept 2021: £327m)		
Operat	H1 2021 H1 2022   93% 87%		CFD BFD £148m £122m	Azule Bridging £17m £45m	SCI	HEMES Om	tier 2 capital <b>£7m</b>
e	LOSS BEFORE TAX OPERATIN		G INCOME	STAFF AND OPERA EXPENSES	ATING	NG NET INTEREST MARGIN	
Financial Performance	<b>£(7.5)m</b> (H1 2021: PROFIT BEFORE TAX £1.4m) <b>£10</b> (H1 2021: £			<b>£15.8m</b> (H1 2021: £8.9m)		<b>5.9%</b> (H1 2021: 6.7%)	
	COST-TO-INCOME RATIO RETURN O		N EQUITY	LOSS PER SHARE		TOTAL CAPITAL RATIO	
	<b>156%</b> (33 (H1 2021: 67%) (H1 2021		<b>1)%</b> <sup>3%)</sup>	(3.0)p (H1 2021: Earnings per share 0.4p)		<b>17.0%</b> (Sep 2021: 17.5%)	

### Actions taken and next steps

#### Legacy challenges faced

- Accounting errors and misstatements, identified during work on the 2020 AR&FS, resulted in trading in the Group's shares being suspended on 19 May 2021.
- Knock-on impact of the delay to 2020 AR&FS publication, alongside the requirements of a first-year audit, led to the late publication of 2021 AR&FS and therefore a further share suspension on 1 April 2022.
- Cost of remediation work has impacted profitability.

#### **Actions taken**

- Finance remediation activities: statutory reporting up to date; FPPP memorandum; Financial Control Framework.
- Cultural improvement programme, focusing on speaking up and responsibility.
- Developed **Risk Management Framework:** filled key second line of defence roles; enhanced stress-testing and credit analytics capabilities.
- Key experienced hires, in particular across Finance, Risk and the Board and Executive team.
- **Prudent capital management,** including management of origination levels to ensure the Group maintains an appropriate level of capital, above the regulatory requirement.

#### Next steps

- Completion of the remediation and transformation programme, focusing on:
  - automation,
  - improving the customer and partner experience, and
  - ensuring that our control framework is fully fit for purpose and embedded
- Leverage **economies of scale** and move towards our ultimate goal of a zero marginal cost operating model once enhanced systems, supported by our new approach to **data-driven decisioning**, are fully implemented.
- Actively exploring strategic opportunities to increase certainty for shareholders and to maximise shareholder value.

Vision: Automated, data-driven and digitalised operations, underpinned by a strengthened culture and control framework, to ensure speed and consistency of service, decision making, and pricing across products.

## **Appendix: financial tables**

### **Consolidated Income Statement**

(£000's)	6 months ended 31 March 2022	6 months ended 31 March 2021 <sup>1</sup>
Interest income <sup>2</sup>	15,891	21,827
Interest expense <sup>2</sup>	(5,859)	(7,517)
Net interest income	10,032	14,310
Fees and commission income	860	958
Fees and commission expense	(570)	(928)
Net fee and commission income	290	30
Net profit on financial instruments at fair value through P&L	375	207
Net operating income	10,697	14,547
Personnel expenses	(9,454)	(5,731)
Depreciation of office equipment, motor vehicles and right-of-use assets	(578)	(575)
Amortisation of intangible assets	(354)	(319)
Impairment loss on software	-	(14)
Other operating expenses	(6,318)	(3,135)
Impairment losses on financial assets	(1,450)	(3,406)
Total operating expenses	(18,154)	(13,180)
(Loss)/profit before tax	(7,457)	1,367
Income tax expense	-	(255)
(Loss)/profit after tax	(7,457)	1,112
Earnings per share – basic & diluted	(3.0)p	0.4p
Statutory return on average equity	(33.1)%	4.3%
Adjusted (loss)/profit before tax <sup>3</sup>	(4,576)	1,898
Adjusted return on average equity <sup>3</sup>	(20.3)%	5.9%

All March-22 and March-21 numbers unaudited

1 The prior period balances have been restated or re-presented for the financial year

2 Interest income and interest expense calculated using the effective interest rate method

3 Adjusted performance metrics represent management's view of underlying performance, as shown in the financial review section of the 2022 Interim Report

### **Consolidated Balance Sheet**

(£000's)	31 March 2022	30 September 2021
Assets		
Cash and balances at central banks	64,196	56,126
Debt instruments at fair value through other comprehensive income	12,132	16,155
Derivative financial instruments	568	209
Loans and advances to customers	320,509	363,992
Office equipment, motor vehicles and right-of-use assets	1,934	2,350
Goodwill and other intangible assets	2,870	3,075
Current tax assets	1,728	1,675
Other assets	2,273	5,169
Total assets	406,210	448,751
Liabilities		
Due to customers	290,712	327,166
Due to banks	59,666	59,630
Lease liabilities	859	1,037
Other liabilities	6,457	4,929
Subordinated liabilities	7,125	7,127
Total liabilities	364,819	399,889
Total equity	41,391	48,862